Troy A. Ignelzi
CIK 1579829 · Chief Financial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$488.2K
Companies
6
Total Filings
46
Lifetime Open-Market Net
-$25.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTNM | Director | — | $14.82 | — | $0 | 4 | 2026-06-26 |
| HRMY | Director | — | $39.52 | — | $0 | 1 | 2026-04-06 |
| RAPP | Chief Financial Officer | 10,000 | $48.82 | $488.2K | $101.0K | 4 | 2026-02-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Chief Financial Officer | 31,907 | $329.83 | $10.52M | -$25.79M | 29 | 2023-08-24 |
| CinCor Pharma, Inc. (CINC) Delisted | Director | — | $29.06 | — | $0 | 1 | 2023-02-24 |
| scPharmaceuticals Inc. (SCPH) Delisted | Chief Financial Officer | — | $5.67 | — | $0 | 1 | 2018-01-19 |
Recent Filings · Page 2 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-06 | — | Notice (144) | −76,357 | -$16.05M | EDGAR |
| 2023-11-28 | — | Notice (144) | −6,000 | -$1.12M | EDGAR |
| 2023-11-21 | — | Notice (144) | −6,000 | -$1.11M | EDGAR |
| 2023-08-24 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | — | -$248.9K | EDGAR |
| 2023-08-22 | — | Notice (144) | −1,500 | -$262.7K | EDGAR |
| 2023-05-25 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | — | -$1.93M | EDGAR |
| 2023-05-23 | — | Notice (144) | −9,000 | -$2.01M | EDGAR |
| 2023-02-24 | CinCor Pharma, Inc. (CINC) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-02-23 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | — | -$1.08M | EDGAR |
| 2023-02-13 | Karuna Therapeutics, Inc. (KRTX) Delisted | Grant (A) | +8,650 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.